
Romina Marone

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7886503/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Targeting phosphoinositide 3-kinase—Moving towards therapy. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2008, 1784, 159-185.	2.3	491
2	5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology. Journal of Medicinal Chemistry, 2017, 60, 7524-7538.	6.4	109
3	Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors. Molecular Cancer Research, 2009, 7, 601-613.	3.4	105
4	PI3KÎ ³ within a nonhematopoietic cell type negatively regulates diet-induced thermogenesis and promotes obesity and insulin resistance. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E854-63.	7.1	55
5	PI3Kγ activity in leukocytes promotes adipose tissue inflammation and early-onset insulin resistance during obesity. Science Signaling, 2017, 10, .	3.6	29
6	Highly Efficient and Versatile Plasmid-Based Gene Editing in Primary T Cells. Journal of Immunology, 2018, 200, 2489-2501.	0.8	28
7	Targeting microRNAs for immunomodulation. Current Opinion in Pharmacology, 2015, 23, 25-31.	3.5	13
8	miRâ€579â€3p Controls Hepatocellular Carcinoma Formation by Regulating the Phosphoinositide 3â€Kinase–Protein Kinase B Pathway in Chronically Inflamed Liver. Hepatology Communications, 2022, 6, 1467-1481.	4.3	8
9	FOXO1 gene involvement in a non-rhabdomyosarcomatous neoplasm. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 1031-1036.	2.8	3
10	Plasmid- or Ribonucleoprotein-Mediated CRISPR/Cas Gene Editing in Primary Murine T Cells. Methods in Molecular Biology, 2021, 2285, 255-264.	0.9	3